DV
Dividend Vision

SRZN Stock — Surrozen Inc

Surrozen Inc (SRZN)

Updated October 16, 2026.

SRZN is a Stock. Total return is -84.5% over the past 5.8 years, 202.1 points behind SPY at 117.6%.

Surrozen is a biotechnology company that discovers and develops antibody-based therapeutics targeting the Wnt pathway to treat tissue repair and disease across multiple organs, with lead candidates in development for eye diseases including diabetic macular edema and age-related macular degeneration, as well as programs in liver, lung, kidney, and other disease areas. The company does not currently distribute to shareholders. Surrozen may appeal to growth-oriented investors seeking exposure to clinical-stage biotechnology development.

SRZN performance versus SPY

Price and return data through 2026-10-16.

Total return is -84.5% over the past 5.8 years, 202.1 points behind SPY at 117.6%. Over the past year its total return — price change plus distributions reinvested — is 72.4%. Its deepest 1-year drawdown was 52.7%.

WindowTotal returnCAGR
1M38.5%—
3M13.0%—
6M-22.7%—
YTD3.7%—
1Y72.4%—
2Y CAGR—49.50%
3Y CAGR—53.50%
5Y CAGR—-24.40%
Since inception (5.8 years)-84.5%-27.70%

SRZN key facts

Asset type
Stock
Asset class
Equity
Inception date
01/11/2021
Distribution frequency
None
Last close
$23.44 (as of 2026-10-16)
Market cap
$275,503,400
Average volume
268991.0
Beta
0.465
Payout ratio
0.0%
EPS
$-38.80

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SRZN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 52.7%.

Who may consider SRZN — and who may not

It is a weaker fit for investors who need monthly cash flow (SRZN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SRZN

Tagged: Healthcare.

Frequently asked questions

Does SRZN pay monthly?

No. SRZN does not currently distribute.

When does SRZN pay a dividend?

SRZN does not currently distribute.

How has SRZN performed?

Total return is -84.5% over the past 5.8 years, 202.1 points behind SPY at 117.6%. Over the past year its total return — price change plus distributions reinvested — is 72.4%. Its deepest 1-year drawdown was 52.7%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.